BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcr

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage bioph

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy an

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "

Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ: BIOA) during the

BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensu

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst cons

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measur

Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the pri

BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concer

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report)'s stock price rose 5.5% on Friday. The stock trad

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral do

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral do

BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra

BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Con

Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgr

Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "th

Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes.

Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology s

BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascu

BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, a

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst cons

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among or

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical da

BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts mai

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear

Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade

Needham analyst Joseph Stringer initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating

Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.72) per share which beat the analyst cons

Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the

Oppenheimer analyst Jay Olson initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Outperform r

Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the p

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Overw

BioAge intends to use the net proceeds from the proposed offering, together with its existing cash,

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biophar

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment bu

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; dem